Watson Laboratories receives FDA approval for Tacrolimus ANDA

NewsGuard 100/100 Score
Jul 2 2010

Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules. Watson intends to begin shipping the product immediately.  

Prograf ® 5 mg had total U.S. sales of approximately $108 million for the twelve months ending May 2010, according to IMS Health.  Tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Lancet Commission predicts sharp increase in global prostate cancer cases
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
New urine-based test improves identification of high-grade prostate cancer
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Common HIV drugs linked to reduced Alzheimer's disease risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Supply chain assessment and management, optimizing pharmaceutical supply chains